COSMO Pharmaceuticals SA Stock Swiss Exchange
Equities
LU1202320294
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- CHF | - |
Mar. 20 | Transcript : Cosmo Pharmaceuticals N.V. - Analyst/Investor Day | |
Mar. 20 | Cosmo Pharmaceuticals N.V. Proposes Dividend Payment for 2024 | CI |
Sales 2023 | 96.72M 103M 94.65M | Sales 2024 * | 262M 280M 256M | Capitalization | 1.24B 1.32B 1.21B |
---|---|---|---|---|---|
Net income 2023 | 1M 1.07M 979K | Net income 2024 * | 111M 119M 109M | EV / Sales 2023 | 8.6 x |
Net cash position 2023 | 48.44M 51.83M 47.4M | Net cash position 2024 * | 110M 118M 108M | EV / Sales 2024 * | 4.31 x |
P/E ratio 2023 |
771
x | P/E ratio 2024 * |
10.6
x | Employees | - |
Yield 2023 |
3.65% | Yield 2024 * |
2.72% | Free-Float | 44.49% |
Latest transcript on COSMO Pharmaceuticals SA
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 61 | 05-12-31 | |
Niall Donnelly
DFI | Director of Finance/CFO | 52 | 16-05-31 |
Chief Tech/Sci/R&D Officer | 54 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
David W Maris
BRD | Director/Board Member | 57 | 21-05-27 |
Founder | 69 | 96-12-31 | |
Director/Board Member | 64 | 05-12-31 |
1st Jan change | Capi. | |
---|---|---|
+25.61% | 672B | |
+25.87% | 570B | |
-5.24% | 360B | |
+16.49% | 321B | |
+8.28% | 300B | |
+7.09% | 217B | |
-9.12% | 204B | |
+5.01% | 199B | |
-8.75% | 149B |